MedTrace Logo

High-resolution CE-MRA of Children's Hip Joint

NCT05754905 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2023-03-06

No results posted yet for this study

Summary

The goal of this observational study is to learn about the feasibility of enhanced three-dimensional water-selective cartilage (3D-WATSc) sequence in displaying the vessels of children's hip by magnetic resonance. The main questions it aims to answer are:

* Could the images of enhanced 3D-WATSc sequence show the healthy side hip joint vessels in children?
* Could the images of enhanced 3D-WATSc sequence show the vascular disease of the suffering side hip joint in children?

Participants with unilateral hip disease will undergo the magnetic resonance examination including enhanced 3D-WATSc sequence. The pelvic plain film and magnetic resonance images will be collected and analysed.

Researchers will compare the images of of the normal side with the images of the abnormal side to see if the enhanced 3D-WATSc sequence images could show the vascular disease of the suffering side hip joint in children?

Conditions

  • Hip
  • Vessels; Anomaly
  • Magnetic Resonance
  • Three-dimensional Water-selective Cartilage (3D-WATSc)

Interventions

OTHER

Magnetic resonance examination

the two groups are underwent magnetic resonance examination including enhanced 3D-WATSc sequence

Sponsors & Collaborators

  • Children's Hospital of Chongqing Medical University

    lead OTHER

Principal Investigators

  • Yuxi Su, M.D. · Children's Hospital of Chongqing Medical University

Eligibility

Min Age
6 Months
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2022-12-30
Completion
2023-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05754905 on ClinicalTrials.gov